Boston Scientific reports Q3 2026 results and cuts FY2026 outlook after cyberattack
Boston Scientific posted third‑quarter 2026 net sales of $5.138 billion, up 1.5% year‑over‑year, with GAAP EPS of $0.40 and adjusted EPS of $0.73. The company said an August 25 cyberattack disrupted manufacturing and order processing, prompting a revision of its full‑year guidance to 4.25% reported sales growth (3.75% organic) and adjusted EPS of $3.16‑$3.18. It also forecast Q4 sales to fall 1%‑3% and adjusted EPS of $0.77‑$0.79.
Why it matters
The lowered FY2026 adjusted EPS guidance falls short of analyst consensus, increasing earnings pressure on the stock. The expected Q4 sales decline signals near‑term revenue weakness, which may weigh on investor sentiment.
Key facts
- 1Q3 2026 net sales were $5.138 billion, a 1.5% increase on a reported, operational and organic basis versus the prior year period. prnewswire.com
- 2GAAP net income attributable to Boston Scientific common stockholders was $0.40 per share. prnewswire.com
- 3Adjusted EPS for the quarter was $0.73 per share. prnewswire.com
- 4Full‑year 2026 sales growth is now estimated at 4.25% on a reported basis and 3.75% on an organic basis. prnewswire.com
- 5Adjusted FY2026 EPS guidance was revised to a range of $3.16 to $3.18 per share. prnewswire.com
- 6Q4 2026 net sales are expected to decline by approximately 1% to 3% versus the prior year period. prnewswire.com
Summary written by AlphAI AI Desk from 20 of 39 sources. Not investment advice. Figures are as stated by the linked sources.